Navigation Links
Progenitor Cell Therapy Secures Industry Accreditation
Date:9/10/2008

dards. We believe this provides a significant advantage to future usability of these cord blood stem cells."

PCT's cord blood banking clients include DomaniCell (www.domanicell.com) and the cord blood companies of Cord Blood America, Inc., including CorCell (www.corcell.com).

In addition to AABB accreditation, PCT's New Jersey facility maintains a Clinical Laboratory License and a license for hematopoietic progenitor cell processing with the New York State Board of Health and with the State of Maryland, a Blood Bank License with the New Jersey Department of Health and Senior Services, and a CLIA license with the Clinical Laboratory Improvement Amendments of the Centers for Medicare & Medicaid Services (CMS). PCT's California facility maintains a drug manufacturing license, which it has held since 2002 with the Food & Drug Branch of the state of California.

Both PCT facilities also maintain FACT Accreditation, a biologics license with the state of California Department of Health, and are registered with the FDA for the manufacture of Human Cells, Tissues, and Cellular and Tissue-Based Products. PCT's quality systems are compliant with FDA's cGMP and cGTP regulations in addition to client-specific SOPs, processes, methods and specifications.

About Progenitor Cell Therapy, LLC
Progenitor Cell Therapy, LLC (PCT) is a client-based company providing cell therapy service solutions for the research, development, manufacturing and commercialization of cell-based therapies. With its cell therapy manufacturing facilities and team of experienced professionals, PCT provides current Good Manufacturing Practices (cGMP)-compliant services for pre-clinical and clinical development, manufacturing, and eventual commercialization of cellular therapies for clients throughou
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Page: 1 2 3 4

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
3. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
4. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
5. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
6. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
7. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
8. Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO
9. Stem Cell Therapy to Skyrocket by 2017
10. Team demos safety of RNA therapy
11. First European IGRT School Takes Place for Radiotherapy Practitioners in UK
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Progenitor Cell Therapy Secures Industry Accreditation
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its ... TECHNOLOGY: GLOBAL MARKETS , the global market for digital ... in 2013. This is estimated to grow to $490 ... rate (CAGR) of 28.6%. , New digital PCR technology ... within the broader PCR field. The opportunities presented by ...
(Date:7/11/2014)... Cayenne Medical, Inc., a privately held ... tissue reconstruction segment, announced the worldwide launch of ... the shoulder and extremities. The SureLock System provides ... method. The unique delivery eliminates manual tensioning that ... anchor displacement (also commonly know as anchor “creep”). ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Understanding the ... channel-expressing cell lines, and the gap that currently exists ... that expand its industry-leading portfolio of validated ion channel ... ion channel-expressing cell lines, as ion channels control many ... control this activity creates the potential to treat a ...
(Date:7/10/2014)... OMICS Group’s 5th International conference and ... 2014 at Double Tree by Hilton Beijing, China is ... Analytical & Bioanalytical research methods only to facilitate improved ... occasion, Dr. Srinubabu Gedela, MD of OMICS Group Inc ... remarkable one in bringing a unique and international mix ...
Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... Pa., Feb. 23 Endo Pharmaceuticals (Nasdaq: ENDP ... by its wholly owned subsidiary, BTB Purchaser Inc., for all ... Inc. (Nasdaq: IDEV ). American Stock Transfer & ... Endo that, as of 5:00 p.m., New York City time, ...
... Calif., Feb. 23 WaferGen Biosystems,Inc. (OTC ... state-of-the-art gene,expression, genotyping, cell biology and stem ... results of the company,s SmartChip Real-Time PCR,System ... 16th,International Molecular Medicine Tri-Conference. The data ...
... Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical ... cancer, inflammation and autoimmune diseases, today announced that Dr. ... as of February 18, 2009. As a result of ... nine members.Dr. Dhingra has been active in oncology clinical ...
Cached Biology Technology:Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period 2Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period 3Data on WaferGen's SmartChip Real-Time PCR System(TM) to be Presented at 16th International Molecular Medicine Tri-Conference 2Data on WaferGen's SmartChip Real-Time PCR System(TM) to be Presented at 16th International Molecular Medicine Tri-Conference 3Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors 2Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors 3Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors 4Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors 5
(Date:7/11/2014)... spider toxins to study the proteins that let nerve ... they have stumbled upon a biological tactic that may ... plagues in a safe and environmentally responsible way. ... lethal for one species and harmless for a closely ... specific pests without harming beneficial species like bees. A ...
(Date:7/10/2014)... 2014  Aware, Inc. (NASDAQ: AWRE ), ... announced on June 26, 2014 that its Board of ... per share, or approximately $40 million in total.  The ... and a payment date of July 24, 2014.  The ... set an ex-dividend date for this special cash dividend. ...
(Date:7/10/2014)... According to the new market research report, ... (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application (Mobile Devices, ... and Geography - Global Trends & Forecasts to 2014 ... Market is projected to cross $14.35 Billion by 2020, ... to 2020. Browse more than 78 market ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... Researchers at the Buck Institute for Age Research ... to treat rodents afflicted with Parkinson,s Disease (PD). ... same group had previously developed, can be used to ... disease and paves the way for the use of ...
... AUGUSTA, Ga. Children at risk for diabetes before they ... bones, Medical College of Georgia researchers report. A study ... exercise found that the 30 percent with signs of poor ... measure of bone strength, said Dr. Norman Pollock, bone biologist ...
... that RNA plays a major role in cell biology, ranging ... as an important tool in functional genomics. Now WIREs RNA, ... providing RNA experts and researchers not only with a title ... to generate new insights and applications. "In the 10 ...
Cached Biology News:Scientists successfully use human induced pluripotent stem cells to treat Parkinson's in rodents 2Diabetes risk in children increases risk for weak bones 2
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selecitivty and potential CNS-Side Effect liabilities of compo...
... tested through 63 ligand ... spanning a broad therapeutic ... includes many non human ... non-selective assays. Used ...
... Receptor (PR) Competitor Assay Kits are ... progesterone receptor binding compounds using fluorescence ... a fusion of glutathione transferase to ... progesterone receptor [PR-LBD(GST)] and a proprietary, ...
... is critical to the maintenance of ... proteins as important and diverse as ... shock and stress response, antigen presentation, ... ion channels, cell cycle regulation, transcription, ...
Biology Products: